Stockreport

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

TG Therapeutics, Inc.  (TGTX) 
Last tg therapeutics, inc. earnings: 11/12 07:34 am Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
PDF NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatmen [Read more]